Alumis

Pharmaceuticals

Company website

Ticker

ALMS.NASDAQ

Market

Foundation year

2021

Employees

109

IPO date

6/13/2024

About

Alumis is dedicated to significantly enhancing patient lives by transitioning from broad immunosuppression to precise therapies. The name "Alumis" reflects this commitment, deriving from the French word "allumer" meaning to illuminate, and "immunis," the Latin term for the immune system.

Headquarters

280 East Grand Avenue South San Francisco, California 94080

Team

Martin Babler - President, Chief Executive Officer and Chairman of the Board, Mark Bradley - Chief Development Officer, Jörn Drappa - Chief Medical Officer, David M Goldstein - Chief Scientific Officer.

Financial information

Underwriters

Morgan Stanley, Leerink, Cantor, Guggenheim Securities

Prospectus